Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Oct 21, 2022 11:27am

172 Views

Post# 35038972

Thinking Out Loud

so who was the big winner by coming out with a new improved formula at the last possible minute (drag it out) the answer is antibe management. it gives them atleast another full year of life for otenaproxesul (did they know the original formula would fail?).if and when it fails the next in line drug will be ready to be the new lead drug. this scheme can be played out for years. they will have to do finacing, bought deals and reverse splits along the way to keep the lights on (none good for share holders "dilution") but hey they want to keep those huge salaries coming in as long as possible, that is how the real game is played. of course i hope iam wrong and they do really have a legit drug that works, time will tell all salaries listed below are in us dollars